| RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature K Temming, RM Schiffelers, G Molema, RJ Kok Drug resistance updates 8 (6), 381-402, 2005 | 627 | 2005 |
| Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status R van der Meel, LJC Vehmeijer, RJ Kok, G Storm, EVB van Gaal Advanced drug delivery reviews 65 (10), 1284-1298, 2013 | 480 | 2013 |
| Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin RM Schiffelers, GA Koning, TLM ten Hagen, MHAM Fens, AJ Schraa, ... Journal of Controlled Release 91 (1-2), 115-122, 2003 | 445 | 2003 |
| Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy M Everts, V Saini, JL Leddon, RJ Kok, M Stoff-Khalili, MA Preuss, ... Nano letters 6 (4), 587-591, 2006 | 323 | 2006 |
| Diverse origins of the myofibroblast—implications for kidney fibrosis LL Falke, S Gholizadeh, R Goldschmeding, RJ Kok, TQ Nguyen Nature Reviews Nephrology 11 (4), 233-244, 2015 | 294 | 2015 |
| Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges F Ramazani, W Chen, CF Van Nostrum, G Storm, F Kiessling, T Lammers, ... International journal of pharmaceutics 499 (1-2), 358-367, 2016 | 280 | 2016 |
| Targeting tumors with nanobodies for cancer imaging and therapy S Oliveira, R Heukers, J Sornkom, RJ Kok, PMPB en Henegouwen Journal of Controlled Release 172 (3), 607-617, 2013 | 248 | 2013 |
| Effect of particle size on drug loading and release kinetics of gefitinib-loaded PLGA microspheres W Chen, A Palazzo, WE Hennink, RJ Kok Molecular pharmaceutics 14 (2), 459-467, 2017 | 235 | 2017 |
| Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis GA Koning, RM Schiffelers, MHM Wauben, RJ Kok, E Mastrobattista, ... Arthritis & Rheumatism 54 (4), 1198-1208, 2006 | 224 | 2006 |
| Preparation and Functional Evaluation of RGD-Modified Proteins as αvβ3 Integrin Directed Therapeutics RJ Kok, AJ Schraa, EJ Bos, HE Moorlag, SA Ásgeirsdóttir, M Everts, ... Bioconjugate chemistry 13 (1), 128-135, 2002 | 221 | 2002 |
| Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α-and IL-1β-induced proinflammatory status of endothelial cells in vitro JM Kułdo, J Westra, SA Asgeirsdóttir, RJ Kok, K Oosterhuis, MG Rots, ... American Journal of Physiology-Cell Physiology 289 (5), C1229-C1239, 2005 | 207 | 2005 |
| Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells MEM Dolman, S Harmsen, G Storm, WE Hennink, RJ Kok Advanced drug delivery reviews 62 (14), 1344-1357, 2010 | 187 | 2010 |
| Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme RJ Kok, F Grijpstra, RB Walthuis, F Moolenaar, D De Zeeuw, DKF Meijer Journal of Pharmacology and Experimental Therapeutics 288 (1), 281-285, 1999 | 180 | 1999 |
| Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats M Moreno, T Gonzalo, RJ Kok, P Sancho‐Bru, M Van Beuge, J Swart, ... Hepatology 51 (3), 942-952, 2010 | 177 | 2010 |
| A Novel Strategy to Modify Adenovirus Tropism and Enhance Transgene Delivery to Activated Vascular Endothelial Cells In Vitro and In Vivo K Ogawara, MG Rots, RJ Kok, HE Moorlag, AM Van Loenen, DKF Meijer, ... Human gene therapy 15 (5), 433-443, 2004 | 177 | 2004 |
| Nanomedicines as cancer therapeutics: current status S Akhter, I Ahmad, MZ Ahmad, F Ramazani, A Singh, Z Rahman, ... Current cancer drug targets 13 (4), 362-378, 2013 | 171 | 2013 |
| Gold nanoparticles in theranostic oncology: current state-of-the-art S Akhter, MZ Ahmad, FJ Ahmad, G Storm, RJ Kok Expert opinion on drug delivery 9 (10), 1225-1243, 2012 | 166 | 2012 |
| Oxidative stress in obstructive nephropathy A Dendooven, DA Ishola Jr, TQ Nguyen, DM Van der Giezen, RJ Kok, ... International journal of experimental pathology 92 (3), 202-210, 2011 | 159 | 2011 |
| Targeting podocyte-associated diseases JW Leeuwis, TQ Nguyen, A Dendooven, RJ Kok, R Goldschmeding Advanced drug delivery reviews 62 (14), 1325-1336, 2010 | 151 | 2010 |
| Peptide-targeted PEG-liposomes in anti-angiogenic therapy A Janssen, RM Schiffelers, TLM Ten Hagen, GA Koning, AJ Schraa, ... International journal of pharmaceutics 254 (1), 55-58, 2003 | 145 | 2003 |